🇺🇸 FDA
Patent

US 12275769

Activatable interleukin 12 polypeptides and methods of use thereof

granted A61KA61K2039/585A61K38/00

Quick answer

US patent 12275769 (Activatable interleukin 12 polypeptides and methods of use thereof) held by Werewolf Therapeutics, Inc. expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Werewolf Therapeutics, Inc.
Grant date
Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/585, A61K38/00